Few studies have examined an association between SNP276 and the risk of metabolic syndrome (MetS), which accelerates the development of diabetic complications, in patients with type II diabetes mellitus (T2DM). This study examined whether the SNP276G4T polymorphism is associated with risk of MetS in 673 Korean patients with T2DM from an ongoing prospective study. Multiple logistic regression analysis revealed that the OR for MetS was greater in patients with the TT genotype than in those with the GG genotype (OR ¼ 2.071; 95% CI ¼ 1.088-3.943) after adjustment of the putative risk factors for MetS. After examining the relationship between serum adiponectin and MetS risk for each genotype, only in patients with the GT genotype, serum adiponectin was negatively associated with the risk of MetS (OR ¼ 0.287; 95% CI ¼ 0.193-0.427). The SNP276G4T polymorphism may have an independent role in the determination of MetS in Korean patients with T2DM.
Introduction
The reduced plasma concentration of adiponectin has been reported in Korean subjects with metabolic syndrome (MetS) phenotypes and in Japanese patients with type II diabetes mellitus (T2DM) (Hotta et al., 2000) . According to recent gene association studies, single-nucleotide polymorphisms (SNP) of the adiponectin gene affect the adiponectin production in adipose tissue and modulate circulating adiponectin, but results are controversial and inconsistent (Yang and Chuang, 2006) . Genetic studies in humans have also provided strong evidence of an association between various SNP of human adiponectin gene and metabolic phenotypes (Yang and Chuang, 2006) . The common adiponectin SNP, 276G4T, in intron 2 is reported to be associated with obesity, MetS, and T2DM among elderly Taiwanese (Yang et al., 2007) and with several components of MetS in non-obese, non-diabetic Koreans (Jang et al., 2008) .
However, no previous study has investigated these associations in patients with T2DM, who are expected to have a greater MetS risk, which may accelerate the development of diabetic complications. Therefore, we investigated the association between the SNP276G4T polymorphism and MetS risk, independently of serum adiponectin and major risk factors for MetS.
Materials and methods
All participants were patients with T2DM who visited one of the two diabetes clinics in Seoul, Korea. For an ongoing prospective study, 847 subjects (aged 40-85 years), without coronary heart or cerebrovascular disease, were randomly selected and interviewed for a baseline investigation from September 2005 to September 2007. In baseline samples, 93 were excluded because no data were available on SNP276 genotypes, BMI, diet, serum adiponectin or MetS parameters, and 81 were excluded with fasting blood glucose o126 mg per 100 ml or HbA1C o6.5%. Therefore, a total of 673 subjects were finally eligible for this analysis. Written informed consent to participation was obtained from each individual. The study protocol was approved by the institutional review board of Yonsei University. MetS was defined using the criteria of the US National Cholesterol Educational Program: Adult Treatment Panel III as X2 of the following: (1) waist circumference X90 cm for men and X80 cm for women; (2) triglyceride X150 mg per 100 ml; (3) HDLcholesterol o40 mg per 100 ml for men and o50 mg per 100 ml for women and (4) systolic X130 mm Hg or diastolic X85 mm Hg blood pressure. Other methods of the study have been described elsewhere (Yu et al., 2007) . In the 673 samples, SNP276 genotype frequencies for GG, GT and TT were 44.4, 46.8 and 8.8%, respectively, similar to those of 45, 47 and 8%, reported previously in Korean patients with T2DM (Lee et al., 2005) . Multivariable-adjusted logistic regression analysis was used to examine the OR for MetS across adiponectin genotypes and across adiponectin levels within each genotype. All analyses were performed using SAS 9.1 software (SAS Inc., Cary, NC, USA).
Results and discussion
Of the 673 Korean patients with T2DM examined, 384 (57. 1%) had MetS (Table 1) . A greater proportion of the GT and TT genotypes, and a lower proportion of the GG genotype were observed in the MetS group. Serum adiponectin were lower in subjects with MetS. Patients with the TT genotype had adiponectin concentrations significantly lower than those with the GT genotype in the non-MetS group and had significantly lower adiponectin than those with the GG genotype in the MetS group. Differences in the serum adiponectin between subjects with and without MetS were observed only in the GT genotype. After adjustment for age, sex and percent energy from carbohydrate, serum adiponectin were negatively associated with MetS risk (OR ¼ 0.508; 95% CI ¼ 0.406-0.636) ( Table 2 ). The adjusted OR for MetS was greater in patients with the TT genotype than in those with the GG genotype and this trend did not change after a further adjustment for serum adiponectin (OR ¼ 2.071; 95% CI ¼ 1.088-3.943). The overall results relating serum adiponectin to MetS risk for each genotype showed that adiponectin was negatively associated with MetS risk only in patients with the GT genotype (OR ¼ 0.287; 95% CI ¼ 0.193-0.427). Although the biologically plausible mechanism of this finding is not clear so far, it is unlikely to be due to chance (Po0.0001).
We found that the T allele of SNP276 was associated with a higher MetS risk, as shown among elderly Taiwanese (Yang et al., 2007) . Inconsistently with our results, previous studies Calculated using a w 2 -test for Hardy-Weinberg equilibrium. f Values were log-transformed before testing. g Calculated using 1-way ANOVA. AB, A and B indicate significant differences between the genotype groups.
in Korea reported significantly higher serum adiponectin in non-diabetic patients with the TT genotype than in those with the GG or GT genotype (Shin et al., 2006; Jang et al., 2008) . However, significant reductions in insulin resistance and increases in adiponectin concentration during weight loss have been observed (Haluzík et al., 2004) , and the same results have been found only in patients with the GG genotype but not in T-allele carriers in overweight or obese Koreans (Shin et al., 2006) . Furthermore, T allele was related to coronary artery disease risk in Italians (Filippi et al., 2005) and TT genotype was associated with cardiovascular disease risk in a subsample of our study population (Yu et al., 2007) . Therefore, the T allele of SNP276 may be related to the risk of MetS and cardiovascular disease in Koreans through reduced adiponectin levels or no improvement of adiponectin concentrations after intervention, such as weight loss.
Our study had several limitations. As this study was conducted in Korean patients with T2DM, these results cannot easily be generalized to other populations. Owing to the nature of a cross-sectional study, it was not possible to determine whether serum adiponectin is a cause or consequence of MetS. To date, however, no study has investigated the association between SNP276 and MetS in patients with T2DM, who have a greater risk of MetS and must be targeted for its prevention for a further prolonged development of diabetic complications.
In conclusion, our results suggest that the SNP276G4T polymorphism may have an independent genetic contributor to MetS in Korean patients with T2DM. A follow-up study should identify the exact role of the SNP276G4T polymorphism in MetS in Korean patients with T2DM. 
